Printer Friendly

CYTOGEN AND CYTORAD: UNDERWRITERS EXERCISE OVER-ALLOTMENT OPTION

 CYTOGEN AND CYTORAD: UNDERWRITERS EXERCISE OVER-ALLOTMENT OPTION
 PRINCETON, N.J., March 9 /PRNewswire/ -- CYTOGEN Corporation (NASDAQ: CYTO) and CYTORAD Incorporated (NASDAQ: CYTDZ), reported today that their underwriters, Merrill Lynch & Co. and Lehman Brothers, have purchased an additional 525,000 units pursuant to an over-allotment option. The over-allotment option is part of a public offering in which 3.5 million units were sold through the underwriters on Feb. 13, 1992, at an initial public offering price of $10 per unit. Each unit consists of one callable common share of CYTORAD Incorporated and one warrant to purchase one common share of CYTOGEN Corporation.
 CYTOGEN is a biopharmaceutical company engaged in the development of proprietary systems utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances in human health care applications. CYTOGEN uses its patented and proprietary antibody "linker" technology to develop specific cancer diagnostic imaging and cancer therapeutic products, as well as certain other products.
 /delval/
 -0- 3/9/92
 /CONTACT: Laura M. Hahn of CYTOGEN, 609-987-8221/
 (CYTO) CO: CYTOGEN Corporation; CYTORAD Incorporated ST: New Jersey IN: MTC SU:


KA -- PH012 -- 6272 03/09/92 09:58 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 9, 1992
Words:188
Previous Article:NORTH AMERICAN BIOLOGICALS LAUNCHES EXPANSION PROGRAM TO MEET RISING DEMAND FOR PLASMA PRODUCTS
Next Article:DU PONT, ALLIED-SIGNAL RESOLVE LAWSUIT
Topics:


Related Articles
CYTOGEN AND CYTORAD FILE UNIT OFFERING
IMMUNOMEDICS ANNOUNCES UNDERWRITERS EXERCISE OVER-ALLOTMENT OPTION
CYTOGEN CORPORATION ANNOUNCES THIRD QUARTER RESULTS
CYTOGEN CORPORATION ANNOUNCES ESTIMATED FOURTH QUARTER RESULTS
CYTOGEN CORPORATION ANNOUNCES SECOND QUARTER RESULTS
CYTOGEN ANNOUNCES RESIGNATION OF MARTIN D. CLEARY
CYTOGEN AND CYTORAD REPORT FAVORABLE RESULTS IN PROSTATE CANCER IMAGING
CYTOGEN AND CYTORAD ANNOUNCE AGREEMENT TO MERGE
CYTOGEN COMMENCES EXCHANGE OFFER FOR CYTORAD UNITS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters